1-氨基-2-甲基胍 | 31106-59-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-氨基-2-甲基胍
• 英文名称: Amino-methyl-guanidin
• 英文别名: 1-Amino-3-methylguanidine；1-amino-2-methylguanidine
• CAS: 31106-59-9
• 化学式: C₂H₈N₄
• mdl: MFCD00179313
• 分子量: 88.1123
• InChiKey: QAUFIQWONOAGSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  76.4
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  1-氨基-2-甲基胍 在 盐酸 、 sodium nitrite 作用下， 生成 1-甲基-5-氨基四氮唑
  参考文献：
  名称：

  Preparation and isomerization of 5-alkylaminotetrazoles

  摘要：

  DOI：

  10.1021/jo50013a002
• 作为产物：
  描述：

  methylcyanamide 在 肼硝酸盐 作用下， 生成 1-氨基-2-甲基胍
  参考文献：
  名称：

  Kitawaki, Nippon Kagaku Zasshi, 1957, vol. 78, p. 1435,1439

  摘要：

  DOI：

文献信息

• H2-Antihistaminika, 35. Mitt. Synthese und H2-antagonistische Wirkung imidazolylmethylthioalkyl-substituierter 1,2,4-Triazole
  作者：Johannes Bonjean、Walter Schunack

  DOI：10.1002/ardp.19873200613

  日期：——

  Es wurden mono‐, di‐ und trisubstituierte 1,2,4‐Triazolderivate dargestellt und auf Histamin‐H2‐antagonistische Aktivität untersucht.

  制备了单、二和三取代的 1,2,4-三唑衍生物并检查了组胺 H2 拮抗活性。
• Synthesis and Biological Activity of Aminoguanidine and Diaminoguanidine Analogues of the Antidiabetic/Antiobesity Agent 3-Guanidinopropionic Acid
  作者：Valerie A. Vaillancourt、Scott D. Larsen、Steven P. Tanis、Jeffery E. Burr、Mark A. Connell、Michele M. Cudahy、Bruce R. Evans、Peter V. Fisher、Paul D. May、Martin D. Meglasson、Deborah D. Robinson、F. Craig Stevens、John A. Tucker、Thomas J. Vidmar、Jen H. Yu

  DOI：10.1021/jm000094n

  日期：2001.4.1

  3-Guanidinopropionic acid (1) has been demonstrated both to improve insulin sensitivity and to promote weight loss selectively from adipose tissue in animal models of non-insulin-dependent diabetes mellitus (NIDDM). However, 1 has also been shown to be a substrate for both the creatine transporter and creatine kinase, leading to marked accumulation in muscle tissue as the corresponding N-phosphate. The corresponding aminoguanidine analogue 2 was recently discovered to retain the antidiabetic activity of 1 while being markedly less susceptible to creatine-like metabolism, suggesting that it should have less potential to accumulate in muscle. Further structural modification of 2 was undertaken to investigate whether the antidiabetic potency could be augmented while maintaining resistance to creatine-like metabolism. Modifications such as a-alkylation, homologation, and bioisosteric replacement of the aminoguanidine all were detrimental to antidiabetic activity. However, the simple regioisomeric aminoguanidinoacetic acid 9 and diaminoguanidinoacetic acid-analogue 7 were found to be equipotent to 2, leading eventually to the discovery of the significantly more potent diaminoguanidinoacetic acid regioisomers 52 and 53. Further attempts to modify the more active template represented by 52 led only to reductions in; antidiabetic activity. Each of the new active analogues displayed the same resistance to creatine-like metabolism as 2. Further testing of 7, 9, and 53 in obese diabetic ob;lob mice confirmed that weight loss is induced selectively from adipose tissue, similar to the lead 1. Administration of 53 to insulin-resistant rhesus monkeys led to reductions in both fasting and post-prandial plasma glucose levels with concomitant reductions in plasma insulin levels, suggesting that the compound improved the action of endogenous insulin. Compounds 7 and 53 were selected for further preclinical development.
• Sympathetic Nervous System Blocking Agents. Derivatives of Guanidine and Related Compounds¹
  作者：James H. Short、Ursula Biermacher、Daniel A. Dunnigan、Thomas D. Leth

  DOI：10.1021/jm00339a013

  日期：1963.5
• Structural Isomerism of Sulfanilylmethylaminoguanidine¹
  作者：Albert H. Greer、G. B. L. Smith

  DOI：10.1021/ja01633a059

  日期：1954.2
• FR2446285
  申请人：——

  公开号：——

  公开（公告）日：——